Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Nuvectis Pharma (NVCT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. : The Nuvectis Pharma (NVCT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Nuvectis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 219.88% HC Wainwright & Co. → $21 Reiterates Buy → Buy 09/15/2023 219.88% HC Wainwright & Co. →
Strong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug Trials
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
Nuvectis Pharma | 10-Q: Quarterly report
Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.40) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 7.41 percent increase over losses of $(0.27
Nuvectis Pharma: Runway Into 2nd Half of 2025 >NVCT
Nuvectis Pharma: Runway Into 2nd Half of 2025 >NVCT
Nuvectis Pharma 1Q Loss $4.17M >NVCT
Nuvectis Pharma 1Q Loss $4.17M >NVCT
Press Release: Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights -- Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARI
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Facts
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib,
Insider Buys Additional US$51k In Nuvectis Pharma Stock
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$51,450 in Common Stocks
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 5,000 shares of Common Stocks on Mar 18, 2024 at an average price of $10.29 for a total value of $51,450.Source: Announcement What is s
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious
Nuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer Treatment
By Chris Wack Nuvectis Pharma shares were up 11% in premarket trading after the company said it saw positive preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with plati
Nuvectis Reports Promising Ovarian Cancer Drug Trial Data
Nuvectis Pharma, Inc. (NASDAQ: NVCT) has announced preliminary results from its Phase 1b clinical trial of NXP800, showcasing encouraging data in the treatment of platinum-resistant, ARID1a-mutated ovarian cancer.
No Data